1-3 of 3
Eric Mou
Close
Sort by
Journal Articles

Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma

Clinical Trials & Observations
Pamela B. Allen, Xinyan Lu, Qing Chen, Kaitlyn O’Shea, Joan S. Chmiel, Liron Barnea Slonim, Madina Sukhanova, Hatice Savas, Andrew M. Evens, Ranjana Advani, Barbara Pro, Reem Karmali, Brett Palmer, Robert A. Bayer, Robert M. Eisner, Eric Mou, Gary Dillehay, Leo I. Gordon, Jane N. Winter
Journal: Blood Advances
Blood Adv (2023) 7 (12): 2670–2676.
https://doi.org/10.1182/bloodadvances.2022008116
Published: 2023
Journal Articles

Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis

Clinical Trials & Observations
Sanjal H. Desai, Raphael Mwangi, Wern Lynn Ng, Rebecca L. King, Matthew J. Maurer, James R. Cerhan, Andrew L. Feldman, Umar Farooq, Eric Mou, Thomas M. Habermann, Carrie A. Thompson, Yucai Wang, Thomas E. Witzig, Grzegorz S. Nowakowski
Journal: Blood Advances
Blood Adv (2022) 6 (24): 6180–6186.
https://doi.org/10.1182/bloodadvances.2022007569
Published: 2022
Includes: Supplemental data
Journal Articles

Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma

Clinical Trials & Observations
Victor M. Orellana-Noia, Krista Isaac, Mary-Kate Malecek, Nancy L. Bartlett, Timothy J. Voorhees, Natalie S. Grover, Steven R. Hwang, N. Nora Bennani, Rachel Hu, Brian T. Hill, Eric Mou, Ranjana H. Advani, Jordan Carter, Kevin A. David, Hatcher J. Ballard, Jakub Svoboda, Michael C. Churnetski, Gabriela Magarelli, Tatyana A. Feldman, Jonathon B. Cohen, Andrew M. Evens, Craig A. Portell
Journal: Blood Advances
Blood Adv (2021) 5 (18): 3623–3632.
https://doi.org/10.1182/bloodadvances.2021004645
Published: 2021
Includes: Supplemental data